Writing effective insurance justification letters for cancer genetic testing: A streamlined approach

Journal of Genetic Counseling

Volumn 10, Issue 4, 2001, Pages 331-341

  Shappell, Heather L ^a   Matloff, Ellen T ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cancer; Genetic counseling; Genetic testing; HNPCC; Insurance

Indexed keywords

EID: 26044455928     PISSN: 10597700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736.
2. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP (1999) Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.JNatl Cancer Inst 17:1040-1046.
3. Lea DH (1999) Client advocacy and collaboration with insurance and laboratory testing agencies: A case study illustrating genetic counselor roles. J Genet Couns 8:175-180.
4. Lerman C, Marshall J, Audrain J, Gomez-Caminero A (1996a) Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. Int J Cancer 69:58-61.
5. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H (1996b) BRCAl testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275:1885-1892.
6. Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, Surdam J, Orinion E, SlominskiCaster S, Watson P, Lerman C, Tonin P, Lenoir G, Serova O, Narod S (1997) A descriptive study of BRCAl testing and reactions to disclosure of test results. Cancer 79:2219-2228.
7. Lynch HT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C, Narod SA (1999) An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91-98.
8. ManleySA, Pennell RL, Frank TS ( 1998) Insurance coverage of BRCAl andBRCA2 sequence analysis (Abstract). J Genet Couns 7:462-463.
9. Matloff ET, Shappell HL, Brierly K, Bernhardt BA, McKinnon W, Peshkin B (2000) What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 18:2484-2492.
10. Schoonmaker MM, Bernhardt BA, Holtzman NA (2000) Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care 16:178-189.
11. Smith WM, Van Orsouw NJ, Fox EA, Kolodner RD, Vijg J, Eng C (1998) Accurate, high-throughput "snapshot" detection of hMLHl mutations by two-dimensional DNA electrophoresis. Genet Test 2:43-53.
12. Steiner CA, Powe NR, Anderson GF, Das A (1997) Technology coverage decisions by health care plans and considerations by medical directors. Med Care 35:472-189.
13. Wingrove KJ, Norris J, Barton PL, Hagerman R (1996) Experiences and attitudes concerning genetic testing and insurance in a Colorado population: A survey of families diagnosed with Fragile X syndrome. Am J Med Genet 64:378-381.